Abstract Number: 2896 • 2017 ACR/ARHP Annual Meeting
Human Cartilage Influences the Crystallization of Monosodium Urate; Understanding the Link between Gout and Osteoarthritis
Background/Purpose: Monosodium urate (MSU) crystal deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. The aim of…Abstract Number: 2898 • 2017 ACR/ARHP Annual Meeting
New Mouse Model of Gout Risk Variant, ABCG2 Q141K, Reveals Unexpectedly Severe Molecular and Functional Defect in ABCG2 Mediated Intestinal Uric Acid Secretion
Background/Purpose: Gout is a common arthritic disease resulting from deposition of monosodium urate crystals in joints and is a consequence of having elevated circulating uric…Abstract Number: 2950 • 2017 ACR/ARHP Annual Meeting
Validation of a Definition for Flare in Patients with Established Gout
Background/Purpose: A standardized validated definition for gout flares (or attacks) is not available. Two provisional definitions published in 2012 were based on patient-reported elements (patient-defined…Abstract Number: 2989 • 2017 ACR/ARHP Annual Meeting
Hydration and Gout: Looking at New Modes of Uric Acid Management
Background/Purpose: Gout affects more than 4% of adults in the United States, and it is the most common form of inflammatory arthritis among men. Studies…Abstract Number: 7L • 2016 ACR/ARHP Annual Meeting
Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Background/Purpose: No clinical trials have previously investigated the frequency of acute flares in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…Abstract Number: 75 • 2016 ACR/ARHP Annual Meeting
Genetic Analysis of Urate Transporters ABCG2, SLC17A3, SLC22A11 and SLC17A1 in Primary Hyperuricemia and Gout
Background/Purpose: The urate transporters are one of the genetic determinants of serum uric acid concentrations. In the present study, we describe the analysis of sequencing…Abstract Number: 161 • 2016 ACR/ARHP Annual Meeting
Are Ultrasound Definitions in Gout Reliable?: Preliminary Results from a Latin American Reliability Exercise
Background/Purpose: Although there is a consistent body of evidence supporting the use of Ultrasound (US) in Gout, several definitions for US lesions have been proposed.…Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…Abstract Number: 198 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…Abstract Number: 199 • 2016 ACR/ARHP Annual Meeting
A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…Abstract Number: 200 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Background/Purpose: Benzbromarone is a potent uricosuric, but is not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand benzbromarone has been available since…Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »